[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-female-participants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-female-participants":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100652630","phase-1-a-study-to-evaluate-the-metabolism-the-routes-and-extent-of-elimination-and-drug-levels-of-14cnavlimetostat-bms-986504-in-healthy-female-participants-100652630",false,"NCT07777133","A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants","A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]Navlimetostat (BMS-986504) at Steady State in Healthy Female Participants","Inclusion Criteria\n\n* Participants must have a body mass index (BMI) of 18.0 to 35.0 kg\u002Fm2, inclusive.\n* Participants must have a recent history (ie, last month) of a minimum of 1 bowel movement per 2 days.\n* Participants must be female (as assigned at birth) who is an individual not of childbearing potential (INOCBP), defined as one of the following:.\n\n  i) Surgically sterile (eg, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).\n\nii) Postmenopausal, defined as ≥ 12 consecutive months of amenorrhea in an individual over the age of 45 years (no other biological or physiological causes), and individuals \\\u003C 55 years of age with 12 months of amenorrhea must have serum FSH levels \\> 40 mIU\u002FmL at screening to confirm menopausal status.\n\nExclusion Criteria\n\n* Participants must not have any significant acute or chronic medical illness.\n* Participants must not have current or recent gastrointestinal disease.\n* Participants must not have a history of prolonged bleeding or excessive bruising.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"FEMALE","18 Years","55 Years",{"count":21,"type":22},6,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to evaluate the metabolism, the routes and extent of elimination, and drug levels of \\[14C\\]Navlimetostat (BMS-986504) in healthy female participants",[28],"Healthy Female Participants",[30,31,32,33,34,35,36,37,38,39,40,41,42],"Protein arginine methyltransferase (PRMT5)","Methylthioadenosine-cooperative PRMT5 inhibitor","Homozygous methylthioadenosine phosphorylase (MTAP) deletion","Mass balance study","Metabolism","Elimination","Drug absorption","Distribution","Excretion","Radiolabeled","Absorption","Excretion (ADME)","Navlimtostat","NOT_YET_RECRUITING","2026-08-18",{"date":46,"type":47},"2026-08-20","ACTUAL",{"date":49,"type":22},"2026-09-16",{"date":51,"type":22},"2026-12-05",{"name":53,"class":54},"Bristol-Myers Squibb","INDUSTRY",2]